<DOC>
	<DOCNO>NCT00675857</DOCNO>
	<brief_summary>The main objective current study establish safety clinical proof-of-concept NC-503 inadequately control patient Type 2 diabetes feature metabolic syndrome treat either metformin , sulfonylurea agent , metformin combination sulfonylurea agent .</brief_summary>
	<brief_title>A Phase IIa Proof-of-concept Study NC-503 Patients With Type II Diabetes</brief_title>
	<detailed_description>Phase IIa Multi-center , randomize , double-blind , placebo-controlled parallel-designed study .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<criteria>Age gender eligibility : 30 year old Diagnosis Type 2 diabetes mellitus Patients treat stable therapeutic dose either metformin , sulfonylurea agent , metformin combination sulfonylurea agent minimum period 3 month prior Screening visit Patients must HbA1C level 7.010.0 % , inclusively screen The participant must central obesity ( Waist circumference ) define per country/ethnic group : Europids : men ≥ 94 cm , woman ≥ 80 cm ; South Asian , Chinese &amp; Japanese : men ≥ 90 cm , woman ≥ 80 cm ; one follow metabolic syndrome characteristic screening : Reduced HDL cholesterol ≤ 1.0 mmol/L Hypertriglyceridemia ≥ 1.7 mmol/L treatment dyslipidemia Hypertension : ≥ 130/85 mm Hg blood pressure treatment antihypertensive medication . Patients must Glomerular Filtration Rate ( GFR ) ≥ 60 mL/min , history dialysis . Patients receive insulin , thiazolidinediones ( TZDs ) nonthiazolidinedione hypoglycemic agent metformin sulfonylurea agent within three month prior screen Has , within last 6 month , evidence significant heart disease stroke , include myocardial infarction , unstable angina , coronary bypass and/or percutaneous transluminal coronary angioplasty ( PTCA ) , congestive heart failure ( New York Heart Association Class IIIIV ) , severe ischemic disease Patients increase red blood cell ( RBC ) turnover Thalassemia anemia Known HIV history viral hepatitis type B C. Any type diabetes Type 2 diabetes Significant hepatic enzyme elevation Body mass index ( BMI ) &gt; 40kg/m2 Current previous use oral injectable corticosteroid , condition require use corticosteroid , three month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Type II diabetes</keyword>
	<keyword>Metabolic syndrome</keyword>
</DOC>